Streptococcus pneumoniae polysaccharide conjugated to corynebacterium diphtheriae CRM197
Highest phase reached
Approved
Drug type
Vaccine component
First approval year
2001
- First approval year
- 2001
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Vaccine component
- Drug name
- Streptococcus pneumoniae polysaccharide conjugated to corynebacterium diphtheriae CRM197
- corynebacterium diphtheriae crm197 protein component of capvaxive
- Corynebacterium diphtheriae crm197 protein component of capvaxive
- prevenar
- Prevenar
- prevenar 13
- Prevenar 13
- Prevenar 20 (previously apexxnar)
- prevenar 20 previously apexxnar
- streptococcus pneumoniae type 10a capsular polysaccharide diphtheria crm197 protein conjugate antigen component of capvaxive
- Streptococcus pneumoniae type 10a capsular polysaccharide diphtheria crm197 protein conjugate antigen component of capvaxive
- streptococcus pneumoniae type 11a capsular polysaccharide diphtheria crm197 protein conjugate antigen component of capvaxive
- Streptococcus pneumoniae type 11a capsular polysaccharide diphtheria crm197 protein conjugate antigen component of capvaxive
- streptococcus pneumoniae type 12f capsular polysaccharide diphtheria crm197 protein conjugate antigen component of capvaxive
- Streptococcus pneumoniae type 12f capsular polysaccharide diphtheria crm197 protein conjugate antigen component of capvaxive
- streptococcus pneumoniae type 15a capsular polysaccharide diphtheria crm197 protein conjugate antigen component of capvaxive
- Streptococcus pneumoniae type 15a capsular polysaccharide diphtheria crm197 protein conjugate antigen component of capvaxive
- streptococcus pneumoniae type 16f capsular polysaccharide diphtheria crm197 protein conjugate antigen component of capvaxive
- Streptococcus pneumoniae type 16f capsular polysaccharide diphtheria crm197 protein conjugate antigen component of capvaxive
- streptococcus pneumoniae type 17f capsular polysaccharide diphtheria crm197 protein conjugate antigen component of capvaxive
- Streptococcus pneumoniae type 17f capsular polysaccharide diphtheria crm197 protein conjugate antigen component of capvaxive
- streptococcus pneumoniae type 19a capsular polysaccharide diphtheria crm197 protein conjugate antigen component of capvaxive
- Streptococcus pneumoniae type 19a capsular polysaccharide diphtheria crm197 protein conjugate antigen component of capvaxive
- streptococcus pneumoniae type 20a capsular polysaccharide diphtheria crm197 protein conjugate antigen component of capvaxive
- Streptococcus pneumoniae type 20a capsular polysaccharide diphtheria crm197 protein conjugate antigen component of capvaxive
- streptococcus pneumoniae type 22f capsular polysaccharide diphtheria crm197 protein conjugate antigen component of capvaxive
And 3 more, listed on the interactive page.
- 7 valent pneumococcal conjugate vaccine prevenar
- Conjugated pneumococcal vaccine (Prevenar)
- conjugated pneumococcal vaccine prevenar
- Pneumococcal 7 valent conjugate vaccine (Prevenar®)
- pneumococcal conjugate vaccine(prevenar)
- prevenar
- Prevenar
- Prevenar (13v)
- Prevenar 13
- Prevenar 13 (2-Dose)
- Prevenar 13 (Single Dose)
- Prevenar 13®
- Prevenar 13™
- Prevenar 20
- Prevenar-13
- Prevenar®
- Prevenar® (7-valent pneumococcal conjugate vaccine)
- Prevenar™
- streptococcus pneumoniae polysaccharide conjugated to corynebacterium diphtheriae crm197
- Streptococcus pneumoniae polysaccharide conjugated to corynebacterium diphtheriae crm197
- streptococcus pneumoniae type 10a capsular polysaccharide diphtheria crm197 protein conjugate antigen
- Streptococcus pneumoniae type 10a capsular polysaccharide diphtheria crm197 protein conjugate antigen
- streptococcus pneumoniae type 11a capsular polysaccharide diphtheria crm197 protein conjugate antigen
- Streptococcus pneumoniae type 11a capsular polysaccharide diphtheria crm197 protein conjugate antigen
- streptococcus pneumoniae type 12f capsular polysaccharide diphtheria crm197 protein conjugate antigen
And 14 more, listed on the interactive page.
- ChEMBL ID
- CHEMBL6068493
- Patents
- 0
- Designations
- 1
- First in class
- No
- Fast track
- No
- Breakthrough designation
- Yes
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
Mechanisms of action
- Mechanism
- Polysaccharide conjugated to Corynebacterium diphtheriae CRM197 vaccine antigen
- Action type
- VACCINE_ANTIGEN
- Target
- Polysaccharide conjugated to Corynebacterium diphtheriae CRM197
- Condition
- Pneumococcal Infections
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000772
- Subject identifier
- D011008
- Condition
- Vaccination
- Highest recorded phase
- 4
- Condition identifier
- EFO:0004292
- Subject identifier
- D014611
- Condition identifier
- EFO_0000772
- Condition identifier
- EFO_0009444
- Highest recorded phase
- 3
- Condition identifier
- HP_0001662
- Highest recorded phase
- 3
- Condition identifier
- HP_0004315
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0000989
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002691
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0003210
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0004619
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004656
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004948
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004986
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005109
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005114
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005441
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005575
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005790
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0007254
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0007256
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0009693
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0018881
- Highest recorded phase
- 2
- Event
- acute chest syndrome
- Reports
- 2
- Reporting signal score
- 10.7722
- Event
- asthma
- Reports
- 5
- Reporting signal score
- 8.14073
- Event
- benign prostatic hyperplasia
- Reports
- 4
- Reporting signal score
- 16.3182
- Event
- blood hiv rna increased
- Reports
- 2
- Reporting signal score
- 8.49045
- Event
- breath sounds abnormal
- Reports
- 4
- Reporting signal score
- 16.4812
- Event
- bronchiectasis
- Reports
- 4
- Reporting signal score
- 14.8877
- Event
- cerebrovascular stenosis
- Reports
- 1
- Reporting signal score
- 5.85269
- Event
- chronic obstructive pulmonary disease
- Reports
- 5
- Reporting signal score
- 11.2308
- Event
- cold type haemolytic anaemia
- Reports
- 2
- Reporting signal score
- 12.2077
- Event
- colitis
- Reports
- 3
- Reporting signal score
- 8.50642
- Event
- congenital hiatus hernia
- Reports
- 4
- Reporting signal score
- 35.271
- Event
- coronary artery disease
- Reports
- 4
- Reporting signal score
- 7.20633
- Event
- cyanosis
- Reports
- 4
- Reporting signal score
- 11.0386
- Event
- drug hypersensitivity
- Reports
- 9
- Reporting signal score
- 9.20734
- Event
- dyspnoea
- Reports
- 12
- Reporting signal score
- 9.282
- Event
- dyspnoea exertional
- Reports
- 4
- Reporting signal score
- 8.31072
- Event
- extensive swelling of vaccinated limb
- Reports
- 1
- Reporting signal score
- 8.03299
- Event
- frequent bowel movements
- Reports
- 3
- Reporting signal score
- 7.91399
- Event
- full blood count abnormal
- Reports
- 4
- Reporting signal score
- 17.4504
- Event
- gastrooesophageal reflux disease
- Reports
- 4
- Reporting signal score
- 6.57452
- Event
- haematochezia
- Reports
- 3
- Reporting signal score
- 8.20514
- Event
- hypercholesterolaemia
- Reports
- 4
- Reporting signal score
- 13.1092
- Event
- hypotonic-hyporesponsive episode
- Reports
- 1
- Reporting signal score
- 6.42402
- Event
- injection site cellulitis
- Reports
- 2
- Reporting signal score
- 8.22568
- Event
- joint injury
- Reports
- 4
- Reporting signal score
- 11.7514
And 18 more, listed on the interactive page.
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (273)
- 13 Valent Pneumococcal Conjugate Vaccine - Follow-on Study
- 13 Valent Pneumococcal Conjugate Vaccine in Chronic Dialysis Patients
- 13-valent Pneumococcal Conjugate Vaccine Study in Adults and Children in India
- 13vPnC Multidose Vial Safety, Tolerability and Immunogenicity Study in Healthy Infants.
- 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Healthy Japanese Infants
- 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants
- 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants
- 20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants
- A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age
- A COHORT STUDY TO EVALUATE IMMUNOGENICITY FOR CHINESE CHILDREN AT THE TIME OF CLINICAL PNEUMONIA DIAGNOSIS
- A Double-Blind Placebo-Controlled Trial of the Safety and Immunogenicity of a Seven Valent Pneumococcal Conjugate Vaccine in Presumed HIV-Infected Infants
- A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine
- A Phase 3 Study to Evaluate the Immunogenicity and Safety of Walvax's PCV13-TT as Compared to Pfizer's PCV13
- A Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Japanese Elderly Adults Aged 65 Years Old and Older
- A Phase I Clinical Study to Evaluate the Safety of PCV26 in Individuals ≥60
- A Phase I Clinical Trial of a 13-valent Pneumococcal Conjugate Vaccine and 14-valent Pneumococcal Conjugate Vaccine in Adults
- A Phase III Clinical Trial of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants
- A Safety And Immunogenicity Study Of A 13-valent Pneumococcal Conjugate Vaccine In Japanese Subjects Aged 6 To 64 Years.
- A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal Vaccine
- A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Subjects